Walsartan – dobry wybór Komentarz
##plugins.themes.bootstrap3.article.sidebar##
Opublikowane:
gru 31, 2017
Słowa kluczowe:
walsartan, choroby sercowo-naczyniowe, niewydolność serca
##plugins.themes.bootstrap3.article.main##
Abstrakt
Obecny na rynku od blisko 30 lat walsartan to jedna z najlepiej przebadanych molekuł należących do grupy antagonistów receptora dla angiotensyny II (ARB). Jego bardzo wysoki profil skuteczności i bezpieczeństwa potwierdzono m.in. u pacjentów z nadciśnieniem tętniczym, chorobą wieńcową czy niewydolnością serca. W świetle najbardziej aktualnych doniesień w połączeniu z inhibitorem neprylizyny zmniejsza ryzyko śmiertelności sercowo-naczyniowej o 20% u pacjentów z niewydolnością serca w stosunku do będącej standardem terapii z wykorzystaniem inhibitora konwertazy angiotensyny I (ACE-I).
##plugins.themes.bootstrap3.article.details##
Jak cytować
Kręcki, R. (2017). Walsartan – dobry wybór . Medycyna Faktów , 10(4(37), 344-347. https://doi.org/10.24292/01.MF.0417.7
Numer
Dział
Artykuły
Copyright © by Medical Education. All rights reserved.
Bibliografia
1. McInnes G.T.: Angiotensin II antagonism in clinical practice: Experience with valsartan. J. Cardiovasc. Pharmacol. 1999; 33: S29-S32.
2. Flesch G., Muller P., Lloyd P.: Absolute bioavailability and pharmacokinetics of valsartan, an angiotensin II receptor antagonist in man. Eur. J. Clin. Pharmcol. 1997; 52: 115-120.
3. Julius S., Kjeldsen S.E., Weber M. et al.; for the VALUE trial group: Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomized trial. Lancet 2004; 363: 2022-2031.
4. Kjeldsen S.E., Julius S., Mancia G. et al.: Effects of valsartan compared to amlodipine on preventing type 2 diabetes in high-risk hypertensive patients: the VALUE trial. J. Hypertens. 2006; 24: 1405-1412.
5. Pfeffer M.A., McMurray J.J.V., Velazquez E.J. et al.: Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N. Engl. J. Med. 2003; 349: 1893-1906.
6. Mistry N.B., Westheim A.S., Kjeldsen S.E.: The angiotensin receptor antagonist valsartan: a review of the literature with a focus on clinical trials. Expert Opin. Pharmacother. 2006; 7: 575-581.
7. Weber M.A.: Comparison of type 1 angiotensin II receptor blockers and angiotensin-converting enzyme inhibitors in the treatment of hypertension. J. Hypertens. 1997; 15: S31-S36.
8. Littlejohn T., Mroczek W., Marbury T. et al.: A prospective, randomized, open-label trial comparing telmisartan 80 mg and valsartan 80 mg in patients with mild to moderate hypertension using ambulatory blood pressure monitoring. Can. J. Cardiol. 2000; 16: 1123-1132.
9. Viberti G., Wheeldon N.M.; MicroAlbuminuria Reduction With VALsartan (MARVAL) Study Investigators: Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure-independent effect. Circulation 2002; 106: 672-678.
10. Vardeny O., Miller R., Solomon S.D.: Combined neprilysin and renin–angiotensin system inhibition for the treatment of heart failure. JACC Heart Fail. 2014; 2: 663-670.
11. Packer M., McMurray J.J.V., Desai A.S. et al.; on behalf of the PARADIGM-HF Investigators and Coordinators: Angiotensin receptor neprilysin inhibition compared with enalapril on the risk of clinical progression in surviving patients with heart failure. Circulation 2015; 131: 54-61.
12. Ponikowski P., Voors A., Anker S. et al.: 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Eur. Heart J. 2016; 37: 2129-2200.
2. Flesch G., Muller P., Lloyd P.: Absolute bioavailability and pharmacokinetics of valsartan, an angiotensin II receptor antagonist in man. Eur. J. Clin. Pharmcol. 1997; 52: 115-120.
3. Julius S., Kjeldsen S.E., Weber M. et al.; for the VALUE trial group: Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomized trial. Lancet 2004; 363: 2022-2031.
4. Kjeldsen S.E., Julius S., Mancia G. et al.: Effects of valsartan compared to amlodipine on preventing type 2 diabetes in high-risk hypertensive patients: the VALUE trial. J. Hypertens. 2006; 24: 1405-1412.
5. Pfeffer M.A., McMurray J.J.V., Velazquez E.J. et al.: Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N. Engl. J. Med. 2003; 349: 1893-1906.
6. Mistry N.B., Westheim A.S., Kjeldsen S.E.: The angiotensin receptor antagonist valsartan: a review of the literature with a focus on clinical trials. Expert Opin. Pharmacother. 2006; 7: 575-581.
7. Weber M.A.: Comparison of type 1 angiotensin II receptor blockers and angiotensin-converting enzyme inhibitors in the treatment of hypertension. J. Hypertens. 1997; 15: S31-S36.
8. Littlejohn T., Mroczek W., Marbury T. et al.: A prospective, randomized, open-label trial comparing telmisartan 80 mg and valsartan 80 mg in patients with mild to moderate hypertension using ambulatory blood pressure monitoring. Can. J. Cardiol. 2000; 16: 1123-1132.
9. Viberti G., Wheeldon N.M.; MicroAlbuminuria Reduction With VALsartan (MARVAL) Study Investigators: Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure-independent effect. Circulation 2002; 106: 672-678.
10. Vardeny O., Miller R., Solomon S.D.: Combined neprilysin and renin–angiotensin system inhibition for the treatment of heart failure. JACC Heart Fail. 2014; 2: 663-670.
11. Packer M., McMurray J.J.V., Desai A.S. et al.; on behalf of the PARADIGM-HF Investigators and Coordinators: Angiotensin receptor neprilysin inhibition compared with enalapril on the risk of clinical progression in surviving patients with heart failure. Circulation 2015; 131: 54-61.
12. Ponikowski P., Voors A., Anker S. et al.: 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Eur. Heart J. 2016; 37: 2129-2200.